Frontier IP Group Plc portfolio companies increased by 34%

Neil Crabb, CEO of Frontier IP Group plc, commented:

“Frontier IP is going from strength to strength. There is strong evidence that our distinctive approach to intellectual property commercialisation, designed to address the needs of both universities and industry, is gaining traction. This fundraising will ensure we can take advantage of future opportunities as they arise. We are confident we are set to make significant progress as the Group and its portfolio companies develop.”

Frontier IP (LON:FIPP), which specialises in commercialising university intellectual property, is pleased to announce that it has raised approximately £2.49 million before expenses through a placing of 3,827,852 new ordinary shares of 10 pence each at an issue price of 65 pence per share.

Transaction highlights

· Placing to raise approximately £2.49 million before expenses

· Strong support from existing and new investors

· The net proceeds of the Placing are intended to be used to build out the core Frontier IP team and strengthen the working capital of the Company

· The Placing Shares will represent approximately 9.09 per cent. of the enlarged issued share capital of the Company

Andrew Richmond, Chairman of Frontier IP Group plc, said:

“I am delighted to announce the successful completion of this fundraising, which was over-subscribed. The support shown by both existing and new shareholders in this placing is very pleasing and a clear endorsement of our business model. I would like to thank our advisers and investors for their support as we enter an exciting period for Frontier IP.”

Summary of and reasons for the Placing

The Company has raised approximately £2.49 million before expenses by means of a Placing with certain new and existing investors of 3,827,852 Placing Shares at 65 pence per share.

The net proceeds of the Placing, estimated to be £2.34 million, are intended to be used to build out the core Frontier IP team and strengthen the working capital of the Company. The Directors believe that the fundraising will help support the Company’s growth by enabling it to continue to develop and grow its portfolio and key relationships.

Results

The Company has today announced results for the 12 months ended 30 June 2018. The key financial highlights for this financial period are as follows:

• Fair value of portfolio companies increased by 34% to £9,041,000 (2017: £6,729,000)

• Total revenue increased by 2% to £2,363,000 (2017: £2,309,000) – reflecting an unrealised profit on the revaluation of investments of £2,064,000 (2017: £2,045,000)

• Revenue from services increased by 13% to £299,000 (2017: £264,000)

• Profit before tax decreased by 27% to £902,000 (2017: £1,229,000)

• Basic earnings per share decreased to 2.36p (2017: 3.73p)

• Cash balances at 30 June 2018 of £1,111,000 (2017: £2,329,000)

• Net assets per share as at 30 June 2018 of 33.2p (2017: 30.7p)

Current trading and outlook

Frontier IP has made highly encouraging progress since its year end. We have grown our portfolio with the addition of three new spinouts, our industry and public-sector partnerships have developed and funding activity within the portfolio continues to pick up pace.

We welcomed our first two spin outs in Portugal, both resulting from our formal relationship with the NOVA University Lisbon – NOVA School of Science and Technology, Portugal. NTPE develops novel technology to print electronic circuits, sensors and semiconductors onto paper and with a team of over 65 researchers it has already been backed with substantial funding. Des Solutio develops safer and greener alternatives to chemicals currently used to make beauty, pharmaceutical and personal care products and the technology has already attracted keen interest from these industries. We are excited by the technologies we are seeing from our university partnerships, both formal and informal, and expect to announce further additions during the year.

Industry partnerships are an important part of our business model, enabling our portfolio companies to validate their technologies to ensure they meet real-world demands. Since our year end, we have continued to see a high level of collaboration with industry across our portfolio companies. This has included Molendotech adding to its industry partnership with Palintest by signing a collaboration agreement with G’s Group, a leading fresh produce company, and Tarsis Technology’s agreement with a global crop protection company to research the use of its metal-organic frameworks technology. We continue to work with our portfolio companies on a number of industry partnerships potentially key to their success.

Ensuring our portfolio companies are appropriately funded is essential to their growth and we are seeing our portfolio attracting funding from both private and public sources. Highlights have included Alusid raising £1.34m of equity finance from new and existing investors to support the planning for a factory to transform its production capacity, and Pulsiv and The Vaccine Group securing grant awards from Innovate UK and the global Bacterial Vaccine Network respectively. We are working on further funding in our portfolio from both private and public sources.

Beyond our work directly with universities as sources of commercialisable IP, our links with the public sector, most recently with our partnership with UK Department for International Trade in Portugal, are valuable to us and our portfolio. We expect to see our engagement across the public sector gaining momentum.

We continue to strengthen our team to support our progress and to enable us to meet demand. In September this year, we were very pleased to welcome Matthew White, former Head of Innovation at AB Sugar, who joined us in a non-board role as Director of Commercialisation.

We are delighted to report continued strong interest from industry, investors, universities and the public sector in the work of our portfolio companies and in Frontier IP itself. Activity and engagement levels with existing and potential partners are rising significantly as we position ourselves for future growth.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Frontier IP Group Plc

    More articles like this

    Frontier IP Group Plc

    Animal Lovers and Zoonotic Diseases: 5 Things to Know

    Zoonotic diseases, or zoonoses, are on the rise. That may first bring to mind exotic diseases like Ebola, but the reality is that many zoonotic infections happen closer to home, often during everyday activities. In 2018,

    Frontier IP Group Plc

    AI-based initiatives catalyzing immunotherapy in 2018

    Artificial intelligence (AI) has been dynamically changing the field of drug discovery in several areas, including immunotherapy, oncotherapy, neurological disease, and many more. Described here is an ensemble of the initiatives in place to advance the field of

    Frontier IP Group Plc

    Frontier IP Group Plc appoint N+1 Singer as sole broker

    Frontier IP Group PLC (LON:FIPP), a specialist in commercialising university intellectual property, today announced the appointment of Nplus1 Singer Advisory LLP as the Group’s sole broker with immediate effect. Allenby Capital Limited remains the Group’s Nominated Adviser.

    Frontier IP Group Plc

    Britain’s university spinout sector is thriving

    They are among Britain’s greatest national treasures and a powerful engine of ideas and innovation for the nation’s booming technology industry. But how good are UK universities at commercialising the research and expertise which springs from

    Frontier IP Group Plc

    Exscientia CEO explains how AI is transforming drug discovery

    In recent decades a strange confluence has formed in the pharmaceutical industry. A range of powerful technologies have brought enormous new capabilities to the sector, productivity has been simultaneously declining. Deloitte’s Centre for Health Solutions estimates that projected returns on investment

    Frontier IP Group Plc

    How technology is revolutionising the healthcare industry

    A technology revolution is transforming the healthcare industry, changing everything from how patients are diagnosed and treated to our battle against some of the world’s most serious diseases. It’s a revolution fuelled by new sources of

    Frontier IP Group Plc

    Artificial Intelligence will Revolutionise Drug Discovery

    New technologies are making their way into the healthcare industry and healthcare providers are already experimenting with advances such as smart pill technology, 3D-printed medication, and mobile apps. But probably the biggest potential lies in artificial intelligence

    Frontier IP Group Plc

    Rallybio forges joint venture with U.K. tech firm

    A Farmington biotech startup formed by a trio of former top Alexion executives said it is working on drug discovery with an artificial intelligence company in the United Kingdom. Rallybio, focused on rare diseases, has not yet publicly

    Frontier IP Group Plc

    What is leptospirosis and how can it harm us and our pets?

    Recently reported cases of the often fatal bacterial infection leptospirosis in dogs in Sydney have raised the issue of animal diseases that also affect humans. This zoonotic disease is spread by rats and other rodents. However, this

    Frontier IP Group Plc

    The Robot Uprising Is Here

    The robot uprising is inevitable. Take the world’s first raspberry-picking robot, an autonomous machine that’s in development by Fieldwork Robotics at the University of Plymouth in the UK. This fruit-picking Terminator, so to speak, was developed for

    Frontier IP Group Plc

    The UK’s 50 Most Disruptive Companies Revealed

    After receiving applications from a wide range of early stage and more established companies from across industries, the initial list was whittled down to 100 by D/SRUPTION. The list was then submitted to an expert judging

    Frontier IP Group Plc

    Artificial intelligence in the world of drug discovery

    Charlotte Walker-Osborn, a Partner and Head of Technology Sector (International) at global law-firm Eversheds Sutherland and a legal expert in technology law, explains some of the challenges and potential future of artificial intelligence (AI) in the

    Frontier IP Group Plc

    11 diseases which can cause infection

    Illnesses that can pass from animals to humans are known as zoonotic. They’re surprisingly common: More than six out of every 10 known infectious diseases in people are actually contracted from animals, according to the CDC.